The family of glycoprotein hormones and their homologous heptahelical receptors represent an excellent system for comparative structure-function studies. We have engineered single chain molecules of human chorionic gonadotropin (hCG) fused to its cognate receptor, LH receptor (LHR), and to the noncognate receptors, TSH receptor (TSHR) and 
T HERE ARE FOUR hormones that comprise the family of human (h) glycoprotein hormones, human chorionic gonadotropin (hCG), LH, TSH, and FSH (1, 2) . These hormones are heterodimers, consisting of a common ␣-subunit and a receptor-specific ␤-subunit, and confer activity by binding to their respective G protein-coupled receptors (GPCRs) (2) . The glycoprotein hormone receptors are a special class of GPCRs, characterized by their relatively large ectodomain, which is responsible for high affinity hormone binding (3) . Because of the high sequence similarity in their ␤-subunits, both hCG and LH bind to the same receptor, LH receptor (LHR), whereas TSH and FSH bind to unique receptors, TSHR and FSHR, respectively (3) . There is a high degree of sequence homology among the glycoprotein hormone ␤-subunits (Fig. 1A) and among the glycoprotein hormone receptor ectodomains (Fig. 1B) .
In 1994, the crystal structure of aglyco-hCG was determined independently by two groups (7, 8) , which was later followed by that of partially glycosylated hFSH (9) . This information has provided a molecular framework for structure-function studies designed to elucidate the regions of these gonadotropins that impart receptor binding and activation.
We and others have used fusion protein techniques to further delve into structure-function studies within the families of glycoprotein hormones and their GPCRs (10, 11) . Single chain, or yoked (Y), hormones have been designed in the manner N-hCG␤-␣-C (10 -12) and N-␣-hCG␤-C (13) (14) (15) . Our group (10) and that of Boime (11) first designed YhCG1 with hCG␤ at the N terminus; we then created YhCG3 in which hCG␤ is located at the C-terminus (13) . Both forms of single chain hCG were effective in activating LHR; however, YhCG1 was able to bind LHR with a higher affinity than that found with YhCG3. This fusion protein technique was later expanded to include yoked hormone-receptor complexes in which YhCG1 and YhCG3 were fused to the N terminus of rat LHR: N-hCG␤-␣-CTP-LHR-C and N-␣-CTP-hCG␤-LHR-C, respectively (13, 16) . This approach of using a fused ligand-receptor complex permits the study of receptor binding and activation by individual subunits, subunit mutants that fail to efficiently form holoproteins, and ligand mutants that bind with low affinity to their cognate receptor.
As the glycoprotein hormones are comprised of a common ␣-subunit and homologous ␤-subunits, and their receptors are homologous as well, we have prepared and characterized fusion proteins of single chain hCG with the three human receptors using the configuration N-␤-␣-CTP-R to yield YCG/LHR, YCG/TSHR, and YCG/FSHR (Fig. 2) to investigate the anticipated weak binding of hCG to and the activation of its noncognate receptors, TSHR and FSHR. Although hCG stimulation of TSHR results in pathophysiological conditions such as gestational hyperthyroidism (17) , there are no known clinical cases involving hCG activation of FSHR. However, the noncognate hormone-receptor interaction involving hCG and TSHR documents that crossreactivity occurs within these families.
The goal of the current study was to comparatively evaluate the ability of hCG to activate each of the human glycoprotein hormone receptors: hLHR, hTSHR, and hFSHR. This information is important in elucidating basic structurefunction relationships of these families of hormones and receptors; furthermore, the information gained should aid in the design of agonists and antagonists for the glycoprotein hormone receptors.
Materials and Methods

Construction of yoked constructs
PCR was used to add a portion of the CTP to the 5Ј end of each of the human glycoprotein hormone receptors as well as an XhoI restriction site to the 3Ј end of each receptor using the following primer designs: 5Ј primer, 5Ј-(AflIII/CTP/factor Xa/human receptor sequence)-3Ј; and 3Ј primer, 5Ј-(human receptor sequence/XhoI)-3Ј. Each of the human glycoprotein hormone receptors was digested with EcoRI and XhoI and then ligated to both YhCG1 that had been digested with BamHI and EcoRI, and pcDNA3 that had been digested with BamHI and XhoI to create vectors containing YCG/LHR, YCG/TSHR, and YCG/FSHR.
Cell culture and transient transfections
HEK 293 cells were grown in monolayer culture in growth medium consisting of DMEM fortified with 10% (vol/vol) newborn calf serum, 10 mm HEPES buffer (pH 7.4), 50 U/ml penicillin, 50 g/ml streptomycin, 50 g/ml fungizone, and 0.125 g/ml amphotericin B. Cells were grown and sustained at 37 C in humidified air containing 5% CO 2 . The cDNAs were transiently transfected using Lipofectamine 2000 as recommended by the manufacturer (Life Technologies, Inc., Grand Island, NY) into 75-cm 2 tissue culture flasks containing HEK 293 cells (5 g cDNA for each fusion protein).
Western blot analysis
Solubilized membrane fractions were electrophoresed on 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membrane was probed with a 1:1000 dilution of an anti-CTP polyclonal antibody (provided by Dr. Vernon Stevens, Ohio State University, Columbus, OH) and visualized by chemiluminescence via a secondary horseradish peroxidase-labeled antirabbit antibody. ]hFSH, respectively, were added to each well containing cells expressing the YCG/R protein or cognate receptor and incubated at 37 C for 6 h. Limited competitive binding studies were also performed with recombinant hCG (Organon, Oss, The Netherlands) and each of the 125 I-labeled hormones and their cognate receptors. Nonspecific binding was determined by the addition of 1 g/ml unlabeled hCG and bTSH and 3 g/ml unlabeled hFSH. The incubation medium was aspirated, and the cells washed with PBS and then lysed by the addition of 0.5 ml 1 n NaOH. All binding assays were performed in duplicate. Mock-transfected cells treated in the same manner were used as negative controls.
Hormone binding
Cell surface antibody binding assay
Approximately 16 -18 h after transfection, the cells were processed as described above, assayed for binding of a receptor-specific primary antibody, raised against a synthetic peptide, and then detected by secondary [
125 I]antirabbit antibody. For hLHR, a 1:4000 dilution of an antirat LHR antibody raised against residues 15-38 (provided by Dr. Patrick Roche, Mayo Medical School, Rochester, MN) was used. Dr. Mariusz Szkudlinski (Trophogen, Inc., Rockville, MD) donated an antihTSHR antibody raised against residues 352-366, and Dr. Mario Ascoli (University of Iowa, Iowa City, IA) provided an antirat FSHR antibody raised against residues 19 -29. Dilutions of 1:1000 and 1:500 were made of the TSHR and FSHR antibodies, respectively. The cells were incubated in the appropriate dilution of the primary antibody, as indicated, in Waymouth's medium with 0.3% (wt/vol) BSA for the LHR antibody and 0.1% (wt/vol) BSA for the TSHR and FSHR antibodies for 4 h at room temperature while shaking. After washing twice with Waymouth's medium containing 0.3% (wt/vol) BSA for the LHR antibody and 0.1% (wt/vol) BSA for the TSHR and FSHR antibodies, the cells were incubated with [
125 I]antirabbit secondary antibody (400,000 cpm/well) in Waymouth's medium containing 0.3% or 0.1% BSA for 1 h at room temperature with shaking. The medium was aspirated, and the cells were washed with PBS after the second incubation period. Lysates were prepared as described above, and the samples were counted in a ␥-counter. Each binding experiment was performed in duplicate.
cAMP assay
The cells were replated and washed as described above some 16 -18 h after transfection, then incubated in Waymouth's medium with 0.1% (wt/vol) BSA and 0.8 mm isobutylmethylxanthine for 15 min at 37 C. The cells were incubated with increasing concentrations of cognate hormone, urinary hCG, bTSH, or hFSH, for 30 min at 37 C in Waymouth's medium containing 0.1% (wt/vol) BSA and 0.8 mm isobutylmethylxanthine immediately following the first incubation. In other studies increasing concentrations of recombinant hCG were added to cells expressing each of the three glycoprotein hormone receptors. The incubation medium was removed, and the cells were lysed in 100% ethanol at Ϫ20 C overnight. The extract was collected, dried under vacuum, and cAMP concentrations were determined by RIA as recommended (NEN Life Science Products, Boston, MA). Each data point was performed in duplicate, and mock-transfected cells were used as negative controls.
Data analysis
Competitive binding and cAMP results were analyzed by nonlinear regression using the PRISM software program (GraphPad Software, Inc., San Diego, CA). The results are given as the mean Ϯ sem, based on three to five independent transfections, and significance was determined by t test. The figures showing competitive binding and hormone-mediated cAMP production are representative experiments. The results in Table  1 refer to the average of each individual parameter from multiple transfections.
Results
Cell surface expression of the yoked hormone-receptor complexes
After transient transfection into HEK 293 cells, membrane preparations of cells expressing YCG/R complexes were prepared. Western blot analysis using a 1:1000 dilution of an anti-CTP antibody showed that all YCG/R proteins were expressed in the molecular mass range of 120 -150 kDa (Fig. 3A) .
To compare cell surface expression levels of the YCG/R complexes with those of their corresponding receptors, the transfected cells were incubated in a solution containing a primary antibody against the extracellular portion of the receptors, whose binding was detected with an 125 I-labeled antirabbit secondary antibody. As shown in Fig. 3B , there were no significant differences in the expression of YCG/R complexes and their corresponding wild-type receptors, signifying that any differences in the functional assays were not due to differences in receptor densities.
Specific binding results for each of the YCG/R complexes and their corresponding wild-type receptors are depicted in Fig. 3C (Fig. 3C) , as expected (13, 16) . These cells, however, exhibited a high constitutive level of cAMP production that was not elevated upon addition of exogenous hormone (Fig. 4) (Fig. 5A) , and no differences were found in the IC 50 values (Table 1 ). An approximately 13-fold increase in basal cAMP in cells expressing YCG/TSHR compared with that seen in cells expressing hTSHR was found. Interestingly, these cells were further stimulated upon addition of exogenous bTSH, and the same maximal cAMP production was observed as that obtained in cells expressing hTSHR (Fig. 5B) (Fig.  6A) . Again, there was no difference in the IC 50 values for hFSHR and YCG/FSHR (Table 1) . Cells expressing YCG/ FSHR exhibited an approximately 4-fold increase in basal cAMP production compared with that of hFSHR; moreover, as with cells expressing YCG/TSHR, those cells were further stimulated after the addition of exogenous hFSH, reaching a maximum cAMP level comparable to that of cells expressing hFSHR (Fig. 6B) . No differences in the ED 50 values were observed (Table 1) .
hCG and hLHR, hTSHR, and hFSHR. As YhCG was able to increase cAMP production in the noncognate receptors, HEK 293 cells were transiently transfected with 5 g cDNA of pcDNA3 for mock-transfected (MT) cells, receptor, or YCG/R. Dose-response curves were performed using hCG, bTSH, or hFSH to compete with a constant level of the corresponding 125 I-labeled hormone. Maximum cAMP levels refer to the maximum production of cAMP when stimulated with 250 ng/ml hCG (LHR) or bTSH (TSHR) or with 1000 ng/ml hFSH (FSHR), with no correction for basal cAMP production. R max values refer to the difference between maximum and basal cAMP levels, showing the amount of cognate ligand-mediated stimulation of the receptors. N/A, Not applicable. The number of independent transfections is in parentheses.
a Results obtained from a previous study (Schubert, R. L., and D. Puett, unpublished data). b The low level of exogenous hCG binding and the high basal cAMP level that is insensitive to added hCG prohibit measurements of IC 50 and ED 50 .
c Significantly different from the corresponding human receptor (P Ͻ 0.05). d Replicate transfections were executed, but only one gave a well defined plateau with a minimum of two points.
hTSHR and hFSHR, experiments were performed to ascertain whether high concentrations of free hCG would also activate these receptors. Figure 7A shows a representative dose-response curve of cAMP production in hLHR-expressing cells at various concentrations of recombinant hCG. Interestingly, high doses of hCG can also lead to minimal activation of hTSHR and hFSHR (Fig. 7B) 
Discussion
The results reported herein demonstrate that there is indeed recognition of hCG by the three glycoprotein hormone receptors. In the yoked hormone-receptor system, hCG binds to and activates not only its cognate receptor, LHR, but also the noncognate receptors, TSHR and FSHR. These findings were confirmed using high concentrations of free, i.e. nonyoked, purified recombinant hCG. Both YCG/TSHR and YCG/FSHR can be further stimulated by the addition of exogenous cognate ligand, indicating that the interactions of hCG, even when fused with a noncognate receptor, were insufficient to prevent cognate hormone binding, as occurs in the homologous system, i.e. [
125 I]hCG binding to YCG/ LHR. However, as all of the glycoprotein hormones share a common ␣-subunit, and there is a high degree of sequence homology in the glycoprotein hormone ␤-subunits and the glycoprotein hormone receptor ectodomains, some degree of cross-reactivity is evidently allowed within this hormone receptor family. An understanding of the differences and similarities between the abilities of these hormones to bind to and activate cognate and noncognate receptors will provide important information not only about the sequence determinants responsible for specificity, but also about common binding and receptor activation elements, e.g. ␣ and conserved ␤ contact sites to identical receptor domains. Such results will help guide the development of small molecule agonists and antagonists for these GPCRs. Figure 1B is arranged to depict the three glycoprotein hormone receptor ectodomains in the context of the model proposed by Bhowmick et al. (5) for that of rat LHR. In their homology model based on the leucine-rich repeat (LRR) structure of pancreatic ribonuclease (18) , residues 27-235 of rat LHR were proposed to form nine LRRs as shown in Fig.  1B for the human receptors. The N-and C-terminal regions of the ectodomain do not exhibit an LRR structure, but it was suggested that a portion of the hinge region may adopt a chemokine-like fold (5) . Identical amino acid residues in the ectodomains of the three glycoprotein hormone receptors are shown by open boxes, and conserved residues, e.g. hydropho- bic, ionizable/identical charge (K/R and D/E), and hydroxylated (S/T), are indicated by shaded boxes.
We know from several studies that high affinity hCG binding to LHR occurs primarily in the region encoded by exons 1-8 (3, 19, 20) . There is, of course, no assurance that the binding of TSH and FSH to their cognate receptor ectodomains will be comparable to that of hCG and the LHR ectodomain. Indeed, in a systematic comparison of the roles of the LRRs in the ectodomains of LHR and FSHR, Song et al. (21) , focusing on LRR1-8, concluded that the Leu/Ile-ϫ-Leu/Ile motifs of the ␤-strands are important, but not equally. Using Ala-scanning mutagenesis of the Leu/Ile residues in the above motif, where there is only one difference between LHR and FSHR in the aligned sequences, they found that hCG binding was eliminated or greatly reduced with Ala replacements of either of the ␤-strand Leu/Ile residues in all eight LRRs of FSHR, whereas LRR5 and -6 of LHR contributed less than the others. Thus, even identical amino acid residues in the three receptor ectodomains may have distinct functions in binding cognate ligands. The same group also showed that LRR4 of LHR contained some amino acid residues critical for hCG binding and others important in signaling (22) . Whether such distinctions will hold for FSHR and TSHR remains to be determined.
A careful examination of Fig. 1B shows that the regions encoded by exons 1 (most of the N-terminal Cys-rich region), 10, and a portion of 11 (most of the C-terminal Cys-rich region) are the most divergent in structure. The three ectodomains contain a highly conserved region encoded by exon 9, L(T/S)YPSHCCAFXN, and an identical region encoded by Table 1 . Values could not be determined for cells expressing YCG/LHR because of the inability of exogenous hCG to bind YCG/LHR.
FIG. 5. Characterization of hTSHR and YCG/TSHR proteins. A, Competitive binding of cells expressing hTSHR and YCG/TSHR. [
125 I]bTSH (50 pM) with increasing concentrations of unlabeled bTSH was used to determine the binding affinity of exogenous bTSH to cells expressing hTSHR or YCG/TSHR. B, cAMP production of cells expressing hTSHR and YCG/TSHR upon stimulation with increasing amounts of bTSH; mock-transfected cells were used as a negative control. IC 50 and ED 50 values are given in Table 1. exon 11, FNPCEDIMGY. Both of these domains have been shown to influence hCG-mediated LHR activation, but not ligand binding (23) (24) (25) (26) . Within the region of the LHR ectodomain believed to be responsible for high affinity ligand binding, the N-terminal Cys-rich region and that of LRR1 and -7 are the most variable and LRR2-6 and -8 exhibit about 55 Ϯ 7% amino acid sequence identity/homology in the three receptors. It is tempting to assign some of the binding specificity to the hormone-specific regions of the ␤-subunits making contacts with the N-terminal Cys-rich region, LRR1 and -7, and portions of LRR2-6 and -8, whereas the ␣-subunit and the identical regions of the ␤-subunits are more likely to have contact sites in the identical/conserved regions of LRR1-8. Those are only suggestions, but they provide a useful framework for data interpretation and to guide further experiments.
A number of amino acid residues on the ␣-and ␤-subunits have been suggested as possible contact sites for cognate receptor binding (2) . The seatbelt regions of the ␤-subunits, identified in the crystal structures of hCG (7, 8) and hFSH (9) , have been studied by several groups using chimeras of the ␤-subunits (27-30) . The results suggest that the N-terminal portion of the seatbelt, i.e. the determinant loop (2), appears more important in hCG binding to LHR, whereas the Cterminal region of the seatbelt has more of an influence on FSH and TSH binding to their cognate receptors. It will be of great interest to determine the contact sites of the seatbelts, if any (29) , with the specific regions of the receptors discussed above.
It is interesting that when yoked to hTSHR and hFSHR, hCG is capable of activating the receptors with minimal, if any, interference with binding of the cognate ligand. This observation may indicate that yoked hCG is capable of partially activating the endodomain or may bind to and activate a region of the ectodomain independent of the site for cognate ligand binding. It is also possible that the low affinity of hCG for hTSHR and hFSHR is amplified in the yoked system, where hCG cannot diffuse far from the receptor ectodomain due to the constraint of the covalent linkage. As the reduced affinity of hCG to the noncognate receptors, relative to the cognate hormones, is probably manifested to some degree by the time of occupancy of the hormone on the receptor-binding site, one would expect a higher rate constant of dissociation of hCG from hTSHR and hFSHR than those of the cognate ligands. In the 30-min cAMP assay, any level of productive binding of yoked hCG to the noncognate receptors could lead to an increase in basal cAMP production. On the other hand, in a 6-h binding assay, the greater affinity of cognate ligand to the yoked hCG-receptor complex, e.g. It is known that in cases of gestational hyperthyroidism hCG is able to bind to and activate TSHR (17) , consistent with our YCG/TSHR findings. Comparative studies of the abilities of hCG and hLH to activate hTSHR expressed in CHO cells showed that both were functional at high concentrations, with hLH being more effective than hCG (31) . The difference was attributable to the hCG␤-CTP. In addition, Rodien et al. (32) showed that a mutation in TSHR, in which Lys 183 is replaced with Arg, increases the receptor's affinity for hCG significantly above that of wild-type hTSHR. Again, this finding supports our studies and exemplifies the importance of the slight differences in primary structure within these families to direct hormone binding and allow for receptor activation. To the best of our knowledge, there are no reported clinical cases in which hypersecretion of hCG activates FSHR, but our results suggest that this can occur.
Yoked hormones and yoked hormone-receptor systems have been used to study interactions within the families of glycoprotein hormones and the glycoprotein hormone receptors. We and others have created YhCG complexes in which the fusion protein has been found to be active in either orientation, N-hCG␤-␣-C (10 -12) and N-␣-hCG␤-C (13) (14) (15) . In addition to single chain TSH (33) and FSH (34) hormones, both of which are as active as the heterodimers, Boime's group has created multifunctional fusion proteins (35, 36) . In one such protein, the common ␣-subunit was fused to FSH␤ and hCG␤, creating a hybrid that could react with FSHR as well as LHR (35) . These studies were then expanded to include a fusion protein that included all three glycoprotein hormone ␤-subunits and a single ␣-subunit to create a trifunctional protein. This protein was found to bind with high affinity to each of the glycoprotein hormone receptors and result in cAMP production (36) .
Although we cannot discount the possibility that the presence of hCG in the YCG/R complexes forces a constraint on receptor conformation that promotes an increase in basal cAMP levels, we do not believe that this happens, based on the documentation of hCG-TSHR interactions (17) as well as the absence of receptor activation when the ␣-subunit, as a monomer or homodimer, was fused to hTSHR (37) . In addition, recent studies from our group showed that the human ␣-subunit, hCG␤, CTP, or PRL, an unrelated protein, when fused to LHR, produced no increase in basal cAMP production (38) . Given these data, we believe that the increases in basal cAMP levels that we have observed are caused by specific interactions of hCG with each of the glycoprotein hormone receptors. Of interest is the observation that YCG/ LHR yields a high basal cAMP that is not increased by the addition of exogenous hormone. This mimics the functional response of many activating mutations of LHR and may reflect the possibility that the conformation of the partially activated receptor is somewhat different from that of the cognate (nonyoked) ligand-receptor complex (39) . There is, unfortunately, no information available on the effects of yoking ligand to receptors (cognate and noncognate) on desensitization and internalization. In summary, the findings from this study have indicated an ability of hCG to bind to and activate its noncognate receptors, hTSHR and hFSHR.
